Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2004 3
2005 4
2006 3
2007 5
2008 5
2009 5
2010 1
2011 7
2012 13
2013 8
2014 9
2015 11
2016 17
2017 16
2018 13
2019 29
2020 12
Text availability
Article attribute
Article type
Publication date

Search Results

141 results
Results by year
Filters applied: . Clear all
Page 1
Intranasal insulin in Alzheimer's dementia or mild cognitive impairment: a systematic review.
Avgerinos KI, Kalaitzidis G, Malli A, Kalaitzoglou D, Myserlis PG, Lioutas VA. Avgerinos KI, et al. J Neurol. 2018 Jul;265(7):1497-1510. doi: 10.1007/s00415-018-8768-0. Epub 2018 Feb 1. J Neurol. 2018. PMID: 29392460 Free PMC article. Review.
BACKGROUND AND AIMS: Due to common pathophysiological findings of Alzheimer's disease (AD) with diabetes mellitus (DM), insulin has been suggested as a possible treatment of AD or mild cognitive impairment (MCI). A safe alternative of IV insulin
BACKGROUND AND AIMS: Due to common pathophysiological findings of Alzheimer's disease (AD) with diabetes mellitus (DM), …
Intranasal insulin in Alzheimer's disease: Food for thought.
Chapman CD, Schiöth HB, Grillo CA, Benedict C. Chapman CD, et al. Neuropharmacology. 2018 Jul 1;136(Pt B):196-201. doi: 10.1016/j.neuropharm.2017.11.037. Epub 2017 Nov 24. Neuropharmacology. 2018. PMID: 29180222 Free article. Review.
Accumulating evidence suggests that disrupted brain insulin signaling promotes the development and progression of Alzheimer's disease (AD), driving clinicians to target this circuitry. ...Furthermore, intranasal delivery elegantly avoids adverse …
Accumulating evidence suggests that disrupted brain insulin signaling promotes the development and progression of Alzheimer' …
Intranasal insulin activates Akt2 signaling pathway in the hippocampus of wild-type but not in APP/PS1 Alzheimer model mice.
Gabbouj S, Natunen T, Koivisto H, Jokivarsi K, Takalo M, Marttinen M, Wittrahm R, Kemppainen S, Naderi R, Posado-Fernández A, Ryhänen S, Mäkinen P, Paldanius KMA, Doria G, Poutiainen P, Flores O, Haapasalo A, Tanila H, Hiltunen M. Gabbouj S, et al. Neurobiol Aging. 2019 Mar;75:98-108. doi: 10.1016/j.neurobiolaging.2018.11.008. Epub 2018 Nov 17. Neurobiol Aging. 2019. PMID: 30554086 Free article.
Type 2 diabetes mellitus (T2DM) increases the risk for Alzheimer's disease (AD). Human AD brains show reduced glucose metabolism as measured by [18F]fluoro-2-deoxy-2-D-glucose positron emission tomography (FDG-PET). ...We found no evidence that a single dose …
Type 2 diabetes mellitus (T2DM) increases the risk for Alzheimer's disease (AD). Human AD brains show reduced glucose m …
Biliverdin Reductase-A Mediates the Beneficial Effects of Intranasal Insulin in Alzheimer Disease.
Barone E, Tramutola A, Triani F, Calcagnini S, Di Domenico F, Ripoli C, Gaetani S, Grassi C, Butterfield DA, Cassano T, Perluigi M. Barone E, et al. Mol Neurobiol. 2019 Apr;56(4):2922-2943. doi: 10.1007/s12035-018-1231-5. Epub 2018 Aug 2. Mol Neurobiol. 2019. PMID: 30073505
Impairment of biliverdin reductase-A (BVR-A) is an early event leading to brain insulin resistance in AD. Intranasal insulin (INI) administration is under evaluation as a strategy to alleviate brain insulin resistance; however, the molecular mechanisms …
Impairment of biliverdin reductase-A (BVR-A) is an early event leading to brain insulin resistance in AD. Intranasal insuli
Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.
Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B. Craft S, et al. Arch Neurol. 2012 Jan;69(1):29-38. doi: 10.1001/archneurol.2011.233. Epub 2011 Sep 12. Arch Neurol. 2012. PMID: 21911655 Free PMC article. Clinical Trial.
OBJECTIVE: To examine the effects of intranasal insulin administration on cognition, function, cerebral glucose metabolism, and cerebrospinal fluid biomarkers in adults with amnestic mild cognitive impairment or Alzheimer disease (AD). ...MAIN OUTCOME …
OBJECTIVE: To examine the effects of intranasal insulin administration on cognition, function, cerebral glucose metabolism, an …
Extracellular Vesicle Biomarkers Track Cognitive Changes Following Intranasal Insulin in Alzheimer's Disease.
Mustapic M, Tran J, Craft S, Kapogiannis D. Mustapic M, et al. J Alzheimers Dis. 2019;69(2):489-498. doi: 10.3233/JAD-180578. J Alzheimers Dis. 2019. PMID: 30958348 Free PMC article. Clinical Trial.
BACKGROUND: Insulin resistance is implicated in Alzheimer's disease (AD), whereas intranasal insulin is an experimental treatment in clinical trials. ...CONCLUSION: Neuronal EV biomarkers of insulin resistance (pS312-IRS-1, pY-IRS- …
BACKGROUND: Insulin resistance is implicated in Alzheimer's disease (AD), whereas intranasal insulin
Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial.
Craft S, Claxton A, Baker LD, Hanson AJ, Cholerton B, Trittschuh EH, Dahl D, Caulder E, Neth B, Montine TJ, Jung Y, Maldjian J, Whitlow C, Friedman S. Craft S, et al. J Alzheimers Dis. 2017;57(4):1325-1334. doi: 10.3233/JAD-161256. J Alzheimers Dis. 2017. PMID: 28372335 Free PMC article. Clinical Trial.
BACKGROUND: Long acting insulin detemir administered intranasally for three weeks enhanced memory for adults with Alzheimer's disease dementia (AD) or amnestic mild cognitive impairment (MCI). ...Secondary outcomes included: global cognition ( …
BACKGROUND: Long acting insulin detemir administered intranasally for three weeks enhanced memory for adults with Alzheimer
Changes in insulin and insulin signaling in Alzheimer's disease: cause or consequence?
Stanley M, Macauley SL, Holtzman DM. Stanley M, et al. J Exp Med. 2016 Jul 25;213(8):1375-85. doi: 10.1084/jem.20160493. Epub 2016 Jul 18. J Exp Med. 2016. PMID: 27432942 Free PMC article. Review.
Individuals with type 2 diabetes have an increased risk for developing Alzheimer's disease (AD), although the causal relationship remains poorly understood. Alterations in insulin signaling (IS) are reported in the AD brain. Moreover, oligomers/fibrils …
Individuals with type 2 diabetes have an increased risk for developing Alzheimer's disease (AD), although the causal re …
Altered Insulin Signaling in Alzheimer's Disease Brain - Special Emphasis on PI3K-Akt Pathway.
Gabbouj S, Ryhänen S, Marttinen M, Wittrahm R, Takalo M, Kemppainen S, Martiskainen H, Tanila H, Haapasalo A, Hiltunen M, Natunen T. Gabbouj S, et al. Front Neurosci. 2019 Jun 18;13:629. doi: 10.3389/fnins.2019.00629. eCollection 2019. Front Neurosci. 2019. PMID: 31275108 Free PMC article. Review.
Alzheimer's disease (AD) and type 2 diabetes (T2D) are both diseases with increasing prevalence in aging populations. T2D, characterized by insulin resistance and defective insulin signaling, is a common co-morbidity and a risk factor for AD, in
Alzheimer's disease (AD) and type 2 diabetes (T2D) are both diseases with increasing prevalence in aging populations. T
Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia.
Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, Callaghan M, Arbuckle M, Behl C, Craft S. Claxton A, et al. J Alzheimers Dis. 2015;44(3):897-906. doi: 10.3233/JAD-141791. J Alzheimers Dis. 2015. PMID: 25374101 Clinical Trial.
Previous trials have shown promising effects of intranasally administered insulin for adults with Alzheimer's disease dementia (AD) or amnestic mild cognitive impairment (MCI). ...The current trial examined whether intranasal insulin
Previous trials have shown promising effects of intranasally administered insulin for adults with Alzheimer's
141 results
Jump to page
Feedback